We are a clinical-stage biopharmaceutical company developing first-in-class therapeutics that target oxidized LDL, an anti-inflammatory approach for treating cardiovascular disease.
Our pipeline focuses on treating patient populations with substantial residual risk of accelerated atherosclerosis, cardiovascular events, and valve disease as a result of chronic inflammation.
Target Oxidized Lipoproteins
Our products target oxidized lipoproteins, such as low-density lipoprotein (oxLDL) and lipoprotein(a). Oxidized lipoproteins are potent inflammatory mediators that are implicated in several inflammatory diseases.
How It Works
Treat Inflammatory Disease
Our clinical and preclinical programs are focused on addressing unmet needs in inflammatory diseases including plaque psoriasis, accelerated atherosclerosis and aortic valve stenosis.